Literature DB >> 9166398

Initiation of hormone replacement therapy after diagnosis of osteoporosis by bone densitometry.

G Phillipov1, E Mos, S Scinto, P J Phillips.   

Abstract

The effect of osteoporosis, as diagnosed by bone densitometry, on general practitioners' decisions to initiate hormone replacement therapy (HRT) was assessed. Data for the study were collected by questionnaire from 147 women (> 40 years), previously referred for measurement of bone mineral density (BMD) at the proximal forearm. Among the women, at the time of BMD measurement, current and ever use of HRT was 35% and 50% respectively, and 25.2% were osteoporotic on the basis of their BMD level. HRT was more likely to be initiated by women who were told that their BMD was low (ODR 3.4; 95% CI 1.2-9.7); 37% of all women with osteoporosis were using HRT compared with 78% who were taking calcium supplements. Potential reasons for the low HRT prescription may include the nature of the BMD report, patient aversion to HRT and doctors' concern with the long-term side-effects of HRT.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9166398     DOI: 10.1007/bf01623693

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  8 in total

1.  Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis.

Authors:  P J Ryan; R Harrison; G M Blake; I Fogelman
Journal:  Br J Obstet Gynaecol       Date:  1992-04

2.  Hormone replacement therapy: compliance and cost after screening for osteoporosis.

Authors:  D J Torgerson; C Donaldson; I T Russell; D M Reid
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1995-03       Impact factor: 2.435

Review 3.  Guidelines for bone densitometry.

Authors:  B E Nordin
Journal:  Med J Aust       Date:  1994-04-18       Impact factor: 7.738

4.  Effects of continuous low-dosage hormonal replacement therapy on lipoprotein metabolism in postmenopausal women.

Authors:  B M Wolfe; M W Huff
Journal:  Metabolism       Date:  1995-03       Impact factor: 8.694

5.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Authors:  G A Colditz; S E Hankinson; D J Hunter; W C Willett; J E Manson; M J Stampfer; C Hennekens; B Rosner; F E Speizer
Journal:  N Engl J Med       Date:  1995-06-15       Impact factor: 91.245

6.  Estrogen replacement therapy and fatal ovarian cancer.

Authors:  C Rodriguez; E E Calle; R J Coates; H L Miracle-McMahill; M J Thun; C W Heath
Journal:  Am J Epidemiol       Date:  1995-05-01       Impact factor: 4.897

7.  The prevalence of oestrogen replacement therapy in South Australia.

Authors:  A H MacLennan; A MacLennan; D Wilson
Journal:  Maturitas       Date:  1993-05       Impact factor: 4.342

Review 8.  Treatment options for osteoporosis.

Authors:  S Khosla; B L Riggs
Journal:  Mayo Clin Proc       Date:  1995-10       Impact factor: 7.616

  8 in total
  6 in total

1.  A population-based study of osteoporosis testing and treatment following introduction of a new bone densitometry service.

Authors:  William D Leslie; Leonard MacWilliam; Lisa Lix; Patricia Caetano; Gregory S Finlayson
Journal:  Osteoporos Int       Date:  2004-10-02       Impact factor: 4.507

2.  Limited utility of clinical indices for the prediction of symptomatic fracture risk in postmenopausal women.

Authors:  Tuan V Nguyen; Jacqueline R Center; Nicholas A Pocock; John A Eisman
Journal:  Osteoporos Int       Date:  2003-10-30       Impact factor: 4.507

3.  Factors related to the use of bone densitometry: survey responses of 494 primary care physicians in New England.

Authors:  D H Solomon; M T Connelly; C J Rosen; B Dawson-Hughes; D P Kiel; S L Greenspan; E S Leib; M Holick; A H Miguel; J S Finkelstein
Journal:  Osteoporos Int       Date:  2003-03-14       Impact factor: 4.507

4.  How are family physicians managing osteoporosis? Qualitative study of their experiences and educational needs.

Authors:  Susan B Jaglal; June Carroll; Gillian Hawker; Warren J McIsaac; Liisa Jaakkimainen; Suzanne M Cadarette; Cathy Cameron; Dave Davis
Journal:  Can Fam Physician       Date:  2003-04       Impact factor: 3.275

5.  Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA.

Authors:  C Asche; R Nelson; C McAdam-Marx; M Jhaveri; X Ye
Journal:  Osteoporos Int       Date:  2009-10-02       Impact factor: 4.507

6.  Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis.

Authors:  Zeren Ma; Yong Li; Ming Zhou; Kedi Huang; Hejun Hu; Xiaoping Liu; Xiaosheng Xu
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.